The labeling states that although the maximum recommended dose of Requip XL is 24mg, patients with advanced Parkinson’s disease should generally be maintained at daily doses of 8mg or lower. Patients with early Parkinson’s disease should generally be maintained at daily doses of 12mg or lower.
Fixed-dose studies, intended to evaluate the dose-response to Requip XL, showed no added therapeutic benefit in patients with advanced stage Parkinson’s disease taking daily doses >8mg/day or among those with early stage Parkinson’s disease taking daily doses >12mg/day.
Requip XL, a non-ergoline dopamine agonist, is indicated to treat Parkinson’s disease. It is available as 2mg, 4mg, 6mg, 8mg, and 12mg strength extended-release tablets.
For more information call (888) 825-5249 or visit GSK.com.